Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
SEC filings, financial facts, source resources, and Goglides workspace context for Aclaris Therapeutics, Inc..
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
111, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenFirst Solar reported FY2025 revenue of $5.2 billion, net income of $1.5 billion and operating cash flow of $2.1 billion. Q1 2026 revenue was $1.0 billion, but operating cash flow was negative, so the thesis depends on module demand, manufacturing execution, po
OpenA source-backed ENPH deep dive covering Q1 2026 revenue, margins, tariffs, cash flow, short interest, IQ9S, PowerMatch, GaN, IQ SST, and the proof gates that decide whether Enphase is a cyclical recovery or still a solar reset story.
OpenAclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.
OpenTag facets appear after tag usage counts are rebuilt.